STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Tuesday reported a loss of $22 million in its first quarter.
The Stamford, Connecticut-based company said it had a loss of 56 cents per share.
The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.
The biotechnology company posted revenue of $4.4 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $5.1 million.
Cara shares have risen 46% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $19, a rise of 48% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CARA at https://www.zacks.com/ap/CARA